VAY736 placebo

BIOLOGICAL2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Rheumatoid ArthritisSystemic Lupus Erythematosus (SLE)

Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of VAY736 in Rheumatoid Arthritis Patients

CompletedNCT02675803

Novartis PharmaceuticalsRheumatoid Arthritis

Start: 2010-12-20End: 2018-01-22Updated: 2020-12-11

Phase 2

Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients

CompletedNCT03656562

Novartis PharmaceuticalsSystemic Lupus Erythematosus (SLE)

Start: 2018-12-19End: 2025-04-28Updated: 2025-10-07

Related Papers

PREEXISTING ANTIBODIES AGAINST VACCINE ANTIGENS ARE PRESERVED IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND SJÖGREN’S DISEASE UPON IANALUMAB TREATMENT WHILE AUTOANTIBODIES DECLINE

The Journal of Rheumatology2025-05-201 citations

IANALUMAB’S DUAL MODE OF ACTION: TARGETING B CELLS THROUGH ENHANCED B CELL DEPLETION AND BLOCKADE OF B CELL-ACTIVATING FACTOR RECEPTOR SIGNALING

The Journal of Rheumatology2025-05-20

P41 Assessment of cognitive function in a randomized, placebo-controlled, interventional trial conducted in patients with moderate-to-severe systemic lupus erythematosus (SLE)

Poster presentations2024-03-01

Ianalumab, a Novel Anti-B-Cell Activating Factor (BAFF) Receptor (BAFF-R) Monoclonal Antibody (mAb) in Development for Immune Thrombocytopenia (ITP) and Warm Autoimmune Hemolytic Anemia (wAIHA), Has Demonstrated a Favorable Safety Profile in Sjögren's Syndrome (SjS), Systemic Lupus Erythematosus (SLE) and Chronic Lymphocytic Leukemia (CLL)

Blood2023-11-025 citations